We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.69%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11B
AUM Growth
+$1.14B
Cap. Flow
+$217M
Cap. Flow %
1.96%
Top 10 Hldgs %
40.32%
Holding
138
New
6
Increased
33
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$152M
2
GILD icon
Gilead Sciences
GILD
+$129M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$102M
4
PBYI icon
Puma Biotechnology
PBYI
+$81.9M
5
ESRX
Express Scripts Holding Company
ESRX
+$72M

Top Sells

Rank Stock Value
1
MOH icon
Molina Healthcare
MOH
+$168M
2
SHPG
Shire pic
SHPG
+$85.9M
3
MCK icon
McKesson
MCK
+$66.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$66.1M
5
COO icon
Cooper Companies
COO
+$55.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Financials 0.18%
3 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
A icon
26
Agilent Technologies
A
$39.9B
$139M 1.26%
3,326,000
-213,000
-6% -$8.24M
LLY icon
27
Eli Lilly
LLY
$1.09T
$136M 1.23%
1,613,000
+341,000
+27% +$28.3M
PFE icon
28
Pfizer
PFE
$144B
$133M 1.21%
4,346,696
+380,494
+10% +$12M
ISRG icon
29
Intuitive Surgical
ISRG
$128B
$131M 1.18%
2,151,000
– –
IRWD icon
30
Ironwood Pharmaceuticals
IRWD
$614M
$130M 1.18%
13,404,322
– –
INSY
31
DELISTED
Insys Therapeutics, Inc.
INSY
$125M 1.13%
4,366,740
+284,940
+7% +$7.89M
COO icon
32
Cooper Companies
COO
$14.2B
$123M 1.11%
3,659,600
-1,546,000
-30% -$55.3M
MGLN
33
DELISTED
Magellan Health Services, Inc.
MGLN
$113M 1.02%
1,833,000
– –
AGN.PRA
34
DELISTED
Allergan plc
AGN.PRA
$107M 0.97%
104,200
– –
WCG
35
DELISTED
Wellcare Health Plans, Inc.
WCG
$105M 0.95%
1,346,200
+1,232,200
+1,081% +$102M
ACHN
36
DELISTED
Achillion Pharmaceuticals
ACHN
$104M 0.94%
9,649,900
+4,427,400
+85% +$40.2M
MNK
37
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$94.2M 0.85%
1,262,000
+89,000
+8% +$5.99M
TSRO
38
DELISTED
TESARO, Inc.
TSRO
$92.3M 0.84%
1,764,700
+29,500
+2% +$1.41M
CYH icon
39
Community Health Systems
CYH
$393M
$89.7M 0.81%
4,092,462
+801,020
+24% +$20.7M
VRTX icon
40
Vertex Pharmaceuticals
VRTX
$125B
$84.7M 0.77%
673,000
+558,000
+485% +$67.4M
IMGN
41
DELISTED
Immunogen Inc
IMGN
$82.7M 0.75%
6,095,647
+2,501,647
+70% +$30.8M
NUVA
42
DELISTED
NuVasive, Inc.
NUVA
$80.5M 0.73%
1,487,000
– –
AFFX
43
DELISTED
Affymetrix Inc
AFFX
$75.8M 0.69%
7,511,000
– –
GKOS icon
44
Glaukos
GKOS
$9.03B
$71.5M 0.65%
2,897,937
– –
MCK icon
45
McKesson
MCK
$105B
$68.9M 0.62%
349,372
-350,628
-50% -$66.2M
PTLA
46
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$67M 0.61%
1,301,700
+317,000
+32% +$15.4M
INSM icon
47
Insmed
INSM
$22.6B
$63M 0.57%
3,469,900
+324,599
+10% +$5.72M
LOXO
48
DELISTED
Loxo Oncology, Inc
LOXO
$61.9M 0.56%
2,175,857
– –
DMTX
49
DELISTED
Dimension Therapeutics, Inc
DMTX
$60.9M 0.55%
+5,397,698
New +$68.3M
BLUE
50
DELISTED
bluebird bio
BLUE
$60.5M 0.55%
72,699
-19,084
-21% -$19.1M
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2015 Portfolio in Review

As of Q4 2015, OrbiMed held 138 positions worth $11B, up 11% from $9.91B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q4 2015 filing shows 6 new, 33 increased, 26 reduced and 8 closed positions. Its largest new stake was Viatris: 3,157,000 shares worth $171M. The largest sale was Molina Healthcare, an estimated $168M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q4 2015 buy was Viatris: 3,157,000 shares worth $171M.
  • OrbiMed added most to Gilead Sciences in Q4 2015, an estimated $129M increase.
  • OrbiMed's biggest Q4 2015 reduction was Molina Healthcare, cutting an estimated $168M.
  • OrbiMed fully exited Chimerix, Inc. in Q4 2015, selling an estimated $39M.
  • OrbiMed's ten largest holdings make up 40% of its $11B portfolio in Q4 2015.
  • OrbiMed opened 6 new positions and closed 8 in Q4 2015.
  • OrbiMed's portfolio value rose 11% quarter-over-quarter to $11B.

Based on OrbiMed's 13F filing for Q4 2015, filed 16 Feb 2016.